Skip to main content

Table 2 Tyrosine kinase and mTOR inhibitor target expression in primary and metastatic RCC samples

From: Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors

Target

AQUA scores, primary specimens (mean ± SD)

AQUA scores, metastatic specimens (mean ± SD)

t-statistic

p-value

B-Raf

32.1 ± 8.9

31.2 ± 10.2

−0.417

0.678

C-Raf

26.7 ± 2.1

28.4 ± 2.5

0.519

0.605

cKit

23.3 ± 1.3

23.4 ± 1.3

0.079

0.937

FGF-R1

29.1 ± 1.1

29.9 ± 0.9

0.579

0.564

HIF-2α

58.2 ± 1.9

58.2 ± 2.0

0.014

0.989

mTOR

18.8 ± 1.4

22.4 ± 1.8

1.637

0.106

PDGF-Rβ

24.7 ± 0.9

27.9 ± 1.5

1.879

0.064

VEGF-R1

22.6 ± 0.9

23.9 ± 1.2

0.34

0.735

VEGF-R2

36.5 ± 2.4

33.5 ± 1.7

−1.294

0.200

VEGF-R3

45.6 ± 2.0

46.5 ± 1.6

0.371

0.712

VEGF

24.7 ± 1.0

26.0 ± 1.1

0.907

0.367

VEGF-B

11.2 ± 0.6

11.8 ± 0.9

0.486

0.628

VEGF-C

17.0 ± 1.3

14.3 ± 1.2

−1.544

0.127

VEGF-D

35.0 ± 1.2

36.8 ± 1.3

1.018

0.312

MEK1

37.5 ± 2.5

50.3 ± 3.1

3.183

0.002

ERK1/2

17.0 ± 1.1

18.6 ± 1.7

0.802

0.425